Advantagene
Latest round
- Series C
Last raised
- Apr 2019
Total raised
- $51M
Investors
- 5
About Advantagene
Based in Massachusetts, US, and was founded in 1999 by Estuardo Aguilar-Cordova., which now trades as Candel Therapeutics, develops cancer immunotherapies to help cancer patients and their families live better lives. Immunotherapies developed by the firm are aimed at preventing cancer recurrence and progression while posing little harm. In clinical studies, the firm is studying the benefits of CAN-2409 therapy for prostate cancer as of July 2021. Candel Therapeutics trades on the NASDAQ under the name CADL. Advantagene, Inc. is a clinical-stage biotechnology firm that develops Gene Mediated Cytotoxic Immunotherapy (GMCI), which causes immunogenic cell death in cancer cells at the injection site and prevents cancer recurrence and progression with minimal side effects. Clinically Advanced Solid Tumor Immunotherapy (CAN-2409) is another product offered by the business, which eliminates the need for complicated immune evasion or tumor-specific targeting mechanisms by focusing the immune response locally towards the tumor. The Phase 3 study for CAN-2409 will be completed in Q3 of 2021, with a final data readout in 2024, according to the firm.
Who invested in Advantagene
5 investors across 2 rounds
See all investors in Advantagene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Advantagene
Who invested in Advantagene?
Advantagene has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Advantagene raised?
Advantagene has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Advantagene last raise money?
Advantagene's most recent round on record is a Series C, in Apr 2019.
What does Advantagene do?
Based in Massachusetts, US, and was founded in 1999 by Estuardo Aguilar-Cordova.
Where is Advantagene headquartered?
Advantagene is headquartered in Needham, US.
Which VCs invest in companies like Advantagene?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Advantagene's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Advantagene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.